Article Sidebar

PDF
Date Published: 27/06/2023
Abstract Views: 318
Views PDF: 141
DOI: https://doi.org/10.51298/vmj.v527i1B.5763
Issue
Vol. 527 No. 1B (2023)
Section
Các bài báo
How to Cite
Đỗ, T. T. L., Masaomi, N., & Lê, V. T. (2023). SURVEY ON URINE ALBUMIN/CREATININE RATIO AND URINE OSMOLALITY IN THE BETA THALASSEMIA PATIENTS. Vietnam Medical Journal, 527(1B). https://doi.org/10.51298/vmj.v527i1B.5763

SURVEY ON URINE ALBUMIN/CREATININE RATIO AND URINE OSMOLALITY IN THE BETA THALASSEMIA PATIENTS

Thị Thanh Loan Đỗ1,, Nangaku Masaomi2, Việt Thắng Lê3
1 Hai Phong University Of Medicine And Pharmacy
2 Tokyo-human university
3 103 Military Hospital

Main Article Content

Abstract

Objectives: Investigation of albumin/creatine ratio and urine osmolality in adults with beta thalassemia. Methods: A cross-sectional descriptive study of 171 subjects including 114 adults with beta thalassemia, 57 healthy subjects as controls. Urine osmolality by early morning urine collection was measured in both the disease and control groups. All patients quantified urinary albumin, creatinine and urinary albumin/creatinine ratio (ACR) in 24-hour urine samples. Results: Urine osmolality in the patient group was 553.5 (419.25 - 722.25) mOsm, lower than the control group 987 (838.5 - 1170) mOsm, p<0.001. The percentage of patients with decreased urine osmolality was 27.2%. In the group of patients, urinary ACR was 0.76 (0.5 - 1.59) mg/mmol, 17.0% (19/114 patients) had ACR level ≥ 3.0 mg/mmol. There is a relationship between urinary ACR ratio, urine osmolality with long time to detect disease, disease severity and plasma ferritin concentration in beta thalassemia patients, p < 0.01. Conclucsion: Renal damage and reduced concentrate function are common in patients with beta thalassemia

Article Details

Keywords

Beta thalassemia, plasma ferritin, urinary albumin/creatinine ratio, urine osmolality

References

1. Bộ Y tế (2014). Hướng dẫn chẩn đoán và điều trị bệnh Thalassemia. Hướng dẫn chẩn đoán và điều trị bệnh Hemophilia và bệnh Thalaseemia: 12-24.
2. Musallam KM, Taher AT. (2012). Mechanisms of Renal Disease in β-Thalassemia. JASN, 23(8): 1299-1302.
3. KDIGO (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements 3: 5-6.
4. Ali BA, Mahmoud AM. (2014). Frequency of glomerular dysfunction in children with Beta thalassaemia major. Sultan Qaboos Univ Med J. 14(1): e88–94.
5. Capolongo G, Zacchia M, Beneduci A, et al. (2020). Urinary Metabolic Profile of Patients with Transfusion-Dependent beta-Thalassemia Major Undergoing Deferasirox Therapy. Kidney Blood Press Res. 45(3):455-466.
6. Nagababu E, Gulyani S, Earley CJ, et al. (2008). Iron- deficiency anaemia enhances red blood cell oxidative stress. Free Radic Res 42: 824- 829.
7. Manotham K, Tanaka T, Matsumoto M, et al. (2004). Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int. 65: 871-880.
8. Sadeghi MV, Mirghorbani M, Akbari R. (2021). β-Thalassemia minor & renal tubular dysfunction: is there any association? BMC Nephrol. 22: 404.
9. Karimi M., Arandi N., Haghpanah S., et al. (2015). Efficacy of Deferasirox (Exjade(R)) in Modulation of Iron Overload in Patients with beta-Thalassemia Intermedia. Hemoglobin. 39:327–329.